Hotspot mutations in NOTCH1 and/or FBXW7 are observed in about 50% of pediatric T-ALL patients and reported to be associated with an improved treatment response or outcome [5, 6]. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.